UK markets open in 6 hours 27 minutes

Abeona Therapeutics Inc. (0H7R.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.1510-0.0293 (-16.25%)
At close: 03:56PM BST

Abeona Therapeutics Inc.

1330 Avenue of the Americas
33rd Floor
New York, NY 10019
United States
646 813 4701
https://www.abeonatherapeutics.com

Sector(s)
Industry
Full-time employees90

Key executives

NameTitlePayExercisedYear born
Dr. Vishwas Seshadri M.B.A., Ph.D.Pres, CEO & Director445.15kN/A1976
Dr. Brendan M. O'Malley J.D., Ph.D.Sr. VP & Gen. Counsel467.37kN/A1969
Mr. Joseph Walter VazzanoCFO, Principal Financial Officer & Principal Accounting OfficerN/AN/A1984
Mr. Brian Kevany Ph.D.VP, CTO & Head of ResearchN/AN/AN/A
Mr. Gregory GinVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Scott SantiamoDirector of Corp. CommunicationsN/AN/AN/A
Ms. Alison HardgroveVP of HRN/AN/AN/A
Mr. Scott Nogi M.B.A.VP & Head of Bus. OperationN/AN/AN/A
Mr. Jon VossVP & Head of QualityN/AN/A1960
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Corporate governance

Abeona Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.